,

Irbeloc 150

Contains: Irbesartan IP 150 mg
Therapeutic Class: Angiotensin II Receptor Blocker (ARB)
Schedule: Schedule H (Prescription Drug)

Irbeloc 150 contains Irbesartan, a potent and long-acting angiotensin II receptor blocker (ARB) used in the management of hypertension, diabetic nephropathy, and cardiovascular risk reduction. By selectively blocking the AT₁ receptors, Irbesartan prevents the vasoconstrictive, aldosterone-secreting, and pro-inflammatory effects of angiotensin II—leading to vasodilation, reduced blood pressure, and renal protection.

Irbesartan has high receptor affinity, a long half-life (11–15 hours), and is suitable for once-daily dosing. It is well-tolerated with minimal risk of cough, unlike ACE inhibitors.

Usage of Irbeloc 150

  • Management of essential hypertension

  • First-line antihypertensive in patients intolerant to ACE inhibitors

  • Diabetic nephropathy in Type 2 diabetes with hypertension and proteinuria

  • Renal protection in hypertensive patients with microalbuminuria

  • May also be used in hypertensive patients at high cardiovascular risk


Common Side Effects

  • Dizziness or light-headedness (especially during initiation)

  • Fatigue

  • Hyperkalemia (rare)

  • Elevated serum creatinine in patients with renal compromise

  • Less commonly: GI discomfort, headache, musculoskeletal pain

Note: Cough and angioedema are significantly less common than with ACE inhibitors.


Precautions

  • Renal function impairment: Monitor creatinine and potassium

  • Volume-depleted patients (e.g., on diuretics): Risk of symptomatic hypotension

  • Hyperkalemia risk: Especially in diabetics or patients on potassium-sparing diuretics

  • Avoid in pregnancy – Category D

  • Use caution in bilateral renal artery stenosis

  • Not recommended for use in children under 18 years without specialist advice


Drug Interactions

  • Potassium supplements / potassium-sparing diuretics: Risk of hyperkalemia

  • NSAIDs: May reduce antihypertensive effect and worsen renal function

  • Lithium: Increased serum lithium levels and toxicity risk

  • Other antihypertensives: Additive BP-lowering effect

  • Minimal CYP450 metabolism — lower interaction risk than many other agents


Dosage and Administration

  • Usual starting and maintenance dose: 150 mg once daily

  • Can be increased to 300 mg once daily if needed for better BP control

  • Taken with or without food

  • Consider lower starting dose (75 mg) in volume-depleted or hemodialysis patients


Storage

  • Store in a cool, dry place below 25°C

  • Protect from light and moisture


Patient Counselling Tips

  • Take medication regularly at the same time each day

  • Do not stop therapy suddenly without physician advice

  • Inform about possible dizziness—especially when rising from sitting/lying position

  • Advise on low-sodium diet and limiting potassium-rich foods/supplements

  • Encourage regular monitoring of BP, kidney function, and electrolytes

Review My Order

0

Subtotal